Dana Narvaez, Oncologist at Alexander Fleming Institute, Global Oncology Subcommittee (Community of Practice – Health Policy) at American Society of Clinical Oncology, shared a post on LinkedIn:
“Our new article, “Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies,” is now out in the International Journal of Molecular Sciences MDPI
In this work with Dr. David Cescon we explore the rapidly evolving post-CDK4/6i treatment landscape for HR+/HER2− metastatic breast cancer, highlighting biomarker-guided strategies and emerging therapeutic options.”
Title: Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies
Authors: Dana P. Narvaez, David W. Cescon
Read the Full Article.
More posts featuring Dana Narvaez.